Literature DB >> 34196737

Effect of lysed and non-lysed sickle red cells on the activation of NLRP3 inflammasome and LTB4 production by mononuclear cells.

Thassila N Pitanga1,2, Sânzio S Santana1,2, Dalila L Zanette3, Caroline C Guarda1, Rayra P Santiago1, Vitor V Maffili1, Jonilson B Lima4, Graziele Q Carvalho1, Jaime R Filho1, Junia R D Ferreira5, Milena M Aleluia6, Valma M L Nascimento7, Magda O S Carvalho8, Isa M Lyra8, Valéria M Borges1, Ricardo R Oliveira1, Marilda S Goncalves9,10.   

Abstract

OBJECTIVE AND
DESIGN: This study tested the hypothesis that sickle red blood cell (SS-RBC) can induce inflammasome NLRP3 components gene expression in peripheral blood mononuclear cells (PBMCs) as well as interleukin-1β (IL-1β) and leukotriene B4 (LTB4) production. Additionally, we investigated the effect of hydroxyurea (HU) treatment in these inflammatory markers.
METHODS: PBMCs from healthy donors (AA-PBMC) were challenged with intact and lysed RBCs from SCA patients (SS-RBC) and from healthy volunteers (AA-RBC). NLRP3, IL-1β, IL-18 and Caspase-1 gene expression levels were assessed by quantitative PCR (qPCR). IL-1β protein levels and LTB4 were measured by ELISA.
RESULTS: We observed that lysed SS-RBC induced the expression of inflammasome NLRP3 components, but this increase was more prominent for CASP1 and IL18 expression levels. Moreover, we observed that intact SS-RBC induced higher production of IL-1β and LTB4 than lysed SS-RBC. Although SCA patients treated with HU have a reduction in NLRP3 gene expression and LTB4 production, this treatment did not modulate the expression of other inflammasome components or IL-1β production.
CONCLUSIONS: Thus, our data suggest that caspase-1, IL-1β and IL-18 may contribute to the inflammatory status observed in SCA and that HU treatment may not interfere in this inflammatory pathway.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Hemolysis; Hydroxyurea; NLRP3-inflammasome; Sickle cell anemia; heme

Mesh:

Substances:

Year:  2021        PMID: 34196737     DOI: 10.1007/s00011-021-01461-2

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  42 in total

1.  HMGB1 takes a "Toll" in sickle cell disease.

Authors:  Kalpna Gupta
Journal:  Blood       Date:  2014-12-18       Impact factor: 22.113

Review 2.  Patrolling monocytes in sickle cell hemolytic conditions.

Authors:  Y Liu; H Zhong; F Vinchi; A Mendelson; K Yazdanbakhsh
Journal:  Transfus Clin Biol       Date:  2019-02-22       Impact factor: 1.406

3.  Interleukin-1β and interleukin-6 gene polymorphisms are associated with manifestations of sickle cell anemia.

Authors:  Perla Vicari; Samuel A Adegoke; Diego Robles Mazzotti; Rodolfo Delfini Cançado; Maria Aparecida Eiko Nogutti; Maria Stella Figueiredo
Journal:  Blood Cells Mol Dis       Date:  2014-12-26       Impact factor: 3.039

4.  Transgenic sickle mice have vascular inflammation.

Authors:  John D Belcher; Christopher J Bryant; Julia Nguyen; Paul R Bowlin; Miroslaw C Kielbik; John C Bischof; Robert P Hebbel; Gregory M Vercellotti
Journal:  Blood       Date:  2003-01-23       Impact factor: 22.113

5.  Endothelial cell P-selectin mediates a proinflammatory and prothrombogenic phenotype in cerebral venules of sickle cell transgenic mice.

Authors:  Katherine C Wood; Robert P Hebbel; D Neil Granger
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-01-02       Impact factor: 4.733

6.  Hemolysis-induced lethality involves inflammasome activation by heme.

Authors:  Fabianno F Dutra; Letícia S Alves; Danielle Rodrigues; Patricia L Fernandez; Rosane B de Oliveira; Douglas T Golenbock; Dario S Zamboni; Marcelo T Bozza
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-15       Impact factor: 11.205

7.  Sickle red cells as danger signals on proinflammatory gene expression, leukotriene B4 and interleukin-1 beta production in peripheral blood mononuclear cell.

Authors:  Thassila N Pitanga; Ricardo R Oliveira; Dalila L Zanette; Caroline C Guarda; Rayra P Santiago; Sanzio S Santana; Valma M L Nascimento; Jonilson B Lima; Graziele Q Carvalho; Vitor V Maffili; Magda O S Carvalho; Luiz C J Alcântara; Valéria M Borges; Marilda S Goncalves
Journal:  Cytokine       Date:  2016-04-02       Impact factor: 3.861

8.  Sickle cell disease increases high mobility group box 1: a novel mechanism of inflammation.

Authors:  Hao Xu; Nancy J Wandersee; YiHe Guo; Deron W Jones; Sandra L Holzhauer; Madelyn S Hanson; Evans Machogu; David C Brousseau; Neil Hogg; John C Densmore; Sushma Kaul; Cheryl A Hillery; Kirkwood A Pritchard
Journal:  Blood       Date:  2014-10-22       Impact factor: 22.113

9.  Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain.

Authors:  James G Taylor; Vikki G Nolan; Laurel Mendelsohn; Gregory J Kato; Mark T Gladwin; Martin H Steinberg
Journal:  PLoS One       Date:  2008-05-07       Impact factor: 3.240

10.  Kommerell's Diverticulum With a Twist: A Case of Recurrent Wheeze in an 8-Year-Old Boy.

Authors:  Tiffany Amber Robles; Aditya Srinivasan; Lynnette Mazur; Anand Gourishankar
Journal:  Glob Pediatr Health       Date:  2019-12-21
View more
  1 in total

Review 1.  Inflammasomes-New Contributors to Blood Diseases.

Authors:  Jaromir Tomasik; Grzegorz Władysław Basak
Journal:  Int J Mol Sci       Date:  2022-07-23       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.